Reversing the "Cold" Tumor Microenvironment in Prostate Cancer

A recent study published in the Journal of Translational Medicine has shed light on the potential mechanisms for reversing the "cold" tumor microenvironment in prostate cancer. Researchers from Beijing Hospital, led by Rui Guo, identified 252 nonsynonymous somatic mutations in the RM-1 murine prostate cancer model, of which 62 mutations had an allele frequency above 60%. The team immunized RM-1 mice with neoantigen peptides, discovering that four epitopes exhibited immunogenicity and three (Med12, Stxbp4, and Hp1bp3) showed therapeutic efficacy in the PCa murine model. This groundbreaking research lays the foundation for the application of neoantigen vaccine immunotherapy in prostate cancer.

Key Takeaways:

• The study identified 252 nonsynonymous somatic mutations in the RM-1 murine prostate cancer model, with 62 mutations having an allele frequency above 60%.
• The researchers immunized RM-1 mice with neoantigen peptides, finding four epitopes to exhibit immunogenicity.
• Three epitopes (Med12, Stxbp4, and Hp1bp3) demonstrated therapeutic efficacy in the PCa murine model.
• The study contributed to an unmet therapeutic need for PCa, particularly its potential mechanisms for reversing "cold" TME.
• The research highlights the role of neoantigen vaccines in reversing "cold" TME, laying the groundwork for future applications in prostate cancer.
• The study included functional immunological experiments and bulk RNA sequencing, which indicated significantly enhanced infiltration and activation of T cells, as well as upregulation of activated immune-related genes.

Statistics:

• 252 nonsynonymous somatic mutations were identified in the RM-1 murine prostate cancer model.
• 62 mutations had an allele frequency above 60%.
• Four epitopes exhibited immunogenicity in the PCa murine model.
• Three epitopes (Med12, Stxbp4, and Hp1bp3) demonstrated therapeutic efficacy in the PCa murine model.
• The study utilized enzyme-linked immunospot assays to assess the immunogenicity of identified neoantigens.
• The research involved in vivo neoantigen vaccination experiments in mice.

Sources:

• Journal of Translational Medicine
• Bmc, Campus, 4 Crinan St, London N1 9XW, England
• BioMed Central - www.biomedcentral.com/
• Journal of Translational Medicine - www.translational-medicine.com
• Beijing Hospital
• Rui Guo
• Center of Biotherapy, Beijing Hospital
• National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, 1007300, People's Republic of China